Intra-cellular therapies presents data from the caplyta adjunctive mdd phase 3 program at the american college of neuropsychopharmacology annual meeting

Presentations complement topline data with new data from two pivotal studies (studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder

ITCI Ratings Summary

ITCI Quant Ranking